Acadia Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Acadia Pharmaceuticals
Public
Traded as NASDAQACAD
Industry Biopharmaceutical, Healthcare
Founded 1993
Headquarters San Diego, CA, U.S.
Key people
Stephen R. Davis
CEO
Products Pimavanserin
Revenue Increase $42.13M (2011)
Increase $22.85M (2011)
Increase $22.76M(2011)
Total assets Increase 108.71M (2012)
Number of employees
95 [1]
Website [2]

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase IV [3] development as a treatment for Parkinson's disease psychosis. It is also developing AGN XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma, both in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development for schizophrenia in collaboration with Meiji Seika Kaisha. The product candidates in the company'’s pipeline emanate from discoveries made using its proprietary drug discovery platform.

Recent Events[edit]

Acadia Pharmaceuticals extended its drug discovery and development research agreement with Allergan to March 2012.[citation needed] The agreement stipulates both parties will work together for the discovery of new therapeutics for glaucoma and ophthalmic conditions.[4]

References[edit]